Cantargia Interim Report for the period 1 Jan 2015 – 31 Mar 2015 available

Cantargia AB interim report for first quarter 2015 is now available on the company web-site (www.cantargia.com). An extract from the report is presented below.

Significant events in the first quarter of 2015
In the beginning of the quarter, an extraordinary general meeting of shareholders was held, where it was decided on a public issue of units prior to a planned listing on Nasdaq First North Stockholm. The subscription period was initiated 27 January and ended 12 February 2015. Subscriptions for SEK 60 million were received, which means that the issue was 136 per cent subscribed, including subscription undertakings. Cantargia raised around SEK 44.1 million before costs through the issue and received about 700 new shareholders. Through the issue, in addition to the 5 800 00 shares, 4 350 000 options of series TO3 and 2 900 000 options of series TO4 were emitted. If fully utilized, Cantargia will receive approximately SEK 55.1 million in 2016.

In the Company Prospectus prior to the listing at Nasdaq First North Stockholm, it was announced that the co-founders Professor Thoas Fioretos and Dr Marcus Järås, due their long term engagement in the Company, intended to sell up to 20 per cent of their shareholdings in Cantargia. In March, the Cantargia announced that Fioretos and Järås had performed this transaction and that their respective ownership after the transaction is approximately 5.5 %. Fioretos and Järås has a long term view on remaining ownership which also include a 12 month lock-up agreement after first day of trading at Nasdaq First North Stockholm.

In March Cantargia was notified that the company had met the requirements for listing on Nasdaq First North Stockholm and that the marketplace had therefore issued its formal approval of the listing. The first day of trading in Cantargia shares and warrants of series TO 3 and TO 4 was 17 March 2015.

Significant events after the end of the period
In April 2015 Cantargia announced that the Company had appointed Lars Thorsson as Vice President Clinical Development. Before joining Cantargia, Lars Thorsson worked at Novo Nordisk A/S, where he held a position of Senior Clinical Pharmacology Scientist with responsibility for preparation and implementation of clinical pharmacological studies in development projects. Lars Thorsson will take up his post on 1 June 2015.

In April Cantargia published a notice of the Company’s annual general meeting, which will be held at Medicon Village on 22 May 2015. On 30 April 2015 Cantargia published its annual report for the financial year 2014. The annual report is available for download at the Company’s website, www.cantargia.com.

First quarter (1 Jan 2015 – 31 Mar 2015)

  • Other operating revenue was SEK 0 (0) thousand.
  • Earnings after financial items were SEK -3,627 (-1,868) thousand.
  • Earnings per share were approximately SEK -0.27 (-10.15).
  • The equity/assets ratio was approximately 95.5 (81.1) per cent.

Definitions

  • Earnings per share: Profit for the period divided by 13,394,874 shares as at 31 March 2015.
  • Equity/assets ratio: Equity divided by total capital.
  • Figures in parentheses refer to same period in the previous year.

Certified Adviser
Sedermera Fondkommission is the company’s Certified Adviser.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE USA, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.

Tags:

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.